Mesenchymal stem cell therapy improves erectile dysfunction in experimental spinal cord injury

Albayrak, Ömercan; Şener, Tarık Emre; Erşahin, Mehmet; Özbaş-Turan, Suna; Ekentok, Ceyda; Tavukçu, Hasan Hüseyin; Çevik, Özge; Çetınel, Şule; Ertaş, Büşra; Şener, Göksel

doi:10.1038/s41443-019-0168-1

Cited by 16 publications

(12 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data are in concordance with preclinical studies that showed stem cells targeting ED-related vasculogenic insufficiencies such as impaired local vasodilation [33], hypoperfusion of sinusoidal spaces [34], and corporeal venous leakage due to veno-occlusive failure [35] through the induction of endothelial cell proliferation secondary to proangiogenic characteristics [33,36,37]. In that context, stem cell therapy generated an increase in the concentration of VEGF [38][39][40][41][42][43][44].…”

Section: Discussionsupporting

confidence: 90%

Intracavernous injection of stem cell-derived bioactive molecules for erectile dysfunction—a pilot phase non-randomized controlled trial

2021

JOMH

View full text Add to dashboard Cite

Background and objective: Experimental and few clinical studies have indicated great potential of stem cell treatments as both a causal and symptomatic approach for the treatment of male erectile dysfunction (ED). We investigated the effect of a one-time injection of stem-cell derived bioactive molecules in patients with self-reported ED. Materials and methods: Twenty self-referred male patients with at least one-year history of ED received a one-time intra-penile injection of acellular stem cell-derived bioactive molecules. ED was evaluated by the International Index of Erectile Function questionnaire (IIEF-5), and quality of life was assessed by the Short-Form-36 questionnaire, (SF-36) at baseline and at 6 months. Six male patients with ED, who received a similar injection using saline served as a historic control. Primary outcome was erectile function as measured by IIEF-5 scores. Secondary outcomes were quality of life, assessed by SF-36 questionnaire. Results: IIEF-5 scores improved from 12.9 ± 4.47 at baseline to 18 ± 3.37 at follow-up (p < 0.05). No significant difference of IIEF-5 scores were observed in the historic controls during the observation period (11 ± 2.53 at baseline vs 10.67 ± 3.5 at follow-up; p > 0.05). Patients, who received stem cell injections, demonstrated significantly enhanced IIEF-5 scores compared to the historic control (p < 0.05). Quality of life scores were significantly improved (role limitations due to physical health issues 56.25 ± 42.82 at baseline vs 68.75 ± 40.45 at follow-up, p < 0.05, energy 51.57 ± 19.33 at baseline vs 57.75 ± 12.3 at follow-up, p < 0.05, emotional wellbeing 56.32 ± 16.28 at baseline vs 68.1 ± 11.73 at follow-up, p < 0.05, and social functioning 67.5 ± 23.79 at baseline vs 76.25 ± 18.98 at follow-up, p < 0.05). Conclusions: A one-time intracavernous acellular stem cell-derived bioactive molecule injection improves IIEF-5 scores and quality of life in men with ED in this small pilot phase study (ClinicalTrials.gov Identifier: NCT04684602).

show abstract

Section: Discussionsupporting

confidence: 90%

Intracavernous injection of stem cell-derived bioactive molecules for erectile dysfunction—a pilot phase non-randomized controlled trial

2021

JOMH

View full text Add to dashboard Cite

show abstract

“…[ 132 ] This positive impact of MSCs resulted in the restoration of motor and sensory functions in SCI models. [ 175–179 ] Furthermore, it was demonstrated that MSCs seeded in different scaffolds transplanted into injured spinal cord facilitate post‐traumatic regeneration of nervous tissue to a greater extent than MSCs infused as a cell suspension. [ 180–182 ]…”

Section: Experimental Attempts To Use Mesenchymal Stem Cells In the Tmentioning

confidence: 99%

Mesenchymal Stem Cells for Neurological Disorders

et al. 2021

View full text Add to dashboard Cite

Neurological disorders are becoming a growing burden as society ages, and there is a compelling need to address this spiraling problem. Stem cell‐based regenerative medicine is becoming an increasingly attractive approach to designing therapies for such disorders. The unique characteristics of mesenchymal stem cells (MSCs) make them among the most sought after cell sources. Researchers have extensively studied the modulatory properties of MSCs and their engineering, labeling, and delivery methods to the brain. The first part of this review provides an overview of studies on the application of MSCs to various neurological diseases, including stroke, traumatic brain injury, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, Parkinson's disease, and other less frequently studied clinical entities. In the second part, stem cell delivery to the brain is focused. This fundamental but still understudied problem needs to be overcome to apply stem cells to brain diseases successfully. Here the value of cell engineering is also emphasized to facilitate MSC diapedesis, migration, and homing to brain areas affected by the disease to implement precision medicine paradigms into stem cell‐based therapies.

show abstract

“…Additionally, MSCs promote synaptic transmission [56], neurite outgrowth, and axonal sprouting mostly by excretion of trophic factors including brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) [12,57]. SCI models motor skills are increased [58] inclusively; bladder and erectile dysfunction improvement have been reported [59,60].…”

Section: Tissue Repairing and Regenerationmentioning

confidence: 99%

Mesenchymal Stem Cells for Clinical Use after Spinal Cord Injury

Soria-Zavala¹,

García–Sánchez²,

Rodríguez-Barrera³

2021

Paraplegia

View full text Add to dashboard Cite

Since multipotential and immunoregulatory properties were identified in mesenchymal stem cells (MSCs) in the twentieth century, they have been proposed as an effective therapy for many degenerative and traumatic diseases such as spinal cord injury (SCI). SCI is a devastating event with a high mortality rate that evokes the loss of motor and sensory functions due to neurochemical imbalance and an exacerbated immune response as a consequence of the initial mechanical damage, which in conjunction creates a hostile microenvironment that inhibits neuronal circuitry restoration. This chapter pretends to lead the reader towards the immunomodulatory, differentiation, and tissue repairing capacities of MSCs that allow them to be a valuable candidate for clinical trials. In the first section, the physiopathology of SCI will be addressed; after that, the chapter will review the general aspects of MSCs such as origin, molecular markers, and the different mechanisms by which MSCs can heal the target tissues. Finally, we will discuss clinical trials involving autologous MSC transplantation and their limitations.

show abstract

Mesenchymal stem cell therapy improves erectile dysfunction in experimental spinal cord injury

Cited by 16 publications

References 28 publications

Intracavernous injection of stem cell-derived bioactive molecules for erectile dysfunction—a pilot phase non-randomized controlled trial

Intracavernous injection of stem cell-derived bioactive molecules for erectile dysfunction—a pilot phase non-randomized controlled trial

Mesenchymal Stem Cells for Neurological Disorders

Mesenchymal Stem Cells for Clinical Use after Spinal Cord Injury

Contact Info

Product

Resources

About